GlaxoSmithKline is planning to cut up to 850 research and development jobs in Britain and the United States, in a bid to improve productivity.
The reduction, equivalent to around 6 percent of the company's overall R&D workforce, is in addition to 350 job cuts announced by the world's second biggest drugmaker in June.
"Following a recent review of business operations, we have started consultation on proposals which could impact 850 roles within R&D in the UK and the U.S.," a spokeswoman said.
More from Ben Hirschler at Reuters
No comments:
Post a Comment